<DOC>
	<DOC>NCT01062620</DOC>
	<brief_summary>A dose escalating phase Ia-b clinical trial of the IGF-1 receptor inhibitor AXL1717 in patients with advanced cancer. The objective is to study the safety and pharmacokinetics of AXL1717 and to define an appropriate Phase 2 dose for further studies. This is the first study in man. The study is not designed to show tumor response.</brief_summary>
	<brief_title>A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>1. At least 18 years of age. 2. Histologically confirmed diagnosis of advanced solid or haematological malignancy not amenable to standard treatment. 3. Pharmacological treatment attempt justified 4. Preserved major organ functions, i.e: BLeukocyte count ≥ 3.0 x 109/L BNeutrophil count ≥ 1.5 x 109/L BPlatelet count ≥ 75 x109/L BHaemoglobin ≥ 100 g/L (transfusions are allowed) PTotal bilirubin level ≤ 1.5 times the upper institutional limit of the "normal" (i.e. reference) range PASAT or PALAT ≤ 2.5 times upper institutional limit of the "normal" range, ≤5 times if liver metastases have been documented PCreatinine ≤ 1.5 times upper institutional limit of the "normal" range 5. Females of childbearing potential should use adequate contraception (oral or injectable contraceptives, hormone releasing intrauterine device) throughout the study period. 6. Signed written informed consent. 1. Ongoing infection or other major recent or ongoing disease that, according to the investigator, poses an unacceptable risk to the patient 2. Known malignancy in CNS 3. Prior antitumour therapy within 4 weeks from enrolment (6 weeks for nitrosurea and MitC). 4. Pregnancy or lactation 5. Current participation in any other interventional clinical trial 6. Performance status &gt; ECOG 2 after optimization of analgesics 7. Life expectancy less than 3 months 8. Contraindications to the investigational product, e.g. known or suspected hypersensitivity. 9. Lack of suitability for participation in the trial, for any reason, as judged by the Investigator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>